Norovirus Infections

7
Pipeline Programs
1
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 6 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vaxart
VaxartSOUTH SAN FRANCISCO, CA
7 programs
4
2
1
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dosePhase 2Vaccine1 trial
VXA-G1.1-NNPhase 1/21 trial
VXA-G1.1-NNPhase 1/21 trial
VXA-G1.1-NNPhase 11 trial
VXA-G1.1-NNPhase 11 trial
+2 more programs
Active Trials
NCT07254728CompletedEst. Dec 2024
NCT05213728CompletedEst. Feb 2022
NCT06944717Active Not RecruitingEst. May 2026
+4 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VaxartOpen label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
VaxartVXA-G1.1-NN
VaxartVXA-G1.1-NN
VaxartVXA-G1.1-NN
VaxartVXA-G1.1-NN
VaxartVXA-G1.1-NN
VaxartVXA-GI.1.NN

Clinical Trials (7)

NCT05626803VaxartOpen label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Start: Jan 2023Est. completion: Oct 2023
Phase 2Completed
NCT05212168VaxartVXA-G1.1-NN

Norovirus Challenge Study

Start: Dec 2021Est. completion: Oct 2023
Phase 1/2Completed
NCT04875676VaxartVXA-G1.1-NN

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

Start: Apr 2021Est. completion: Feb 2022
Phase 1/2Completed
NCT06944717VaxartVXA-G1.1-NN

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

Start: Mar 2025Est. completion: May 2026
Phase 1Active Not Recruiting
NCT07254728VaxartVXA-G1.1-NN

A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

Start: Oct 2023Est. completion: Dec 2024
Phase 1Completed
NCT05213728VaxartVXA-G1.1-NN

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

Start: Jan 2022Est. completion: Feb 2022
Phase 1Completed
NCT04854746VaxartVXA-GI.1.NN

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

Start: Apr 2021Est. completion: Jan 2022
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space